Zheng Yao
Financieel Directeur/CFO bij Taizhou EOC Pharma Co., Ltd.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Xu Jing Su | M | 41 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 5 jaar |
Xiao Ming Zou | M | 57 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 14 jaar |
Xin Ni | M | 53 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 14 jaar |
Hong Yan Wang | F | 57 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 4 jaar |
Qing Xu | M | 53 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 4 jaar |
Qiang Zhou | M | 58 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 4 jaar |
He Ting Li | M | 49 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 12 jaar |
Huan Yang | M | 41 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 5 jaar |
Cui Ping Gu | M | 44 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 7 jaar |
Ting Fu | F | 32 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 5 jaar |
Song Zhou | M | 43 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 5 jaar |
Miao Jie Chen | F | 41 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 7 jaar |
Wen Kong | M | 57 |
Taizhou EOC Pharma Co., Ltd.
Taizhou EOC Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Taizhou EOC Pharma Co., Ltd. engages in the research and development, and sale of drugs for tumor treatment. Its business segments include clinical trial research, pharmaceutical production, drug discovery and product introduction, drug registration, and product sales and commercialization. Its Clinical Trial Research segment involves in the clinical plan formulation, patient inclusion and exclusion criteria design, and primary and secondary endpoint indicators selection. Its Pharmaceutical Production segment supplies entinostat clinical trial drugs. Its Drug Discovery and Product Introduction segment implements drug discovery and research. Its Drug Registration segment manages product registration with drug regulatory department. Its Product Sales and Commercialization segment offers pharmaceutical academic promotion and sales agency assistance for pharmaceutical companies. The company was founded by Xin Ni and Xiao Ming Zou on October 21, 2010 and is headquartered in Taizhou, China. | 6 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Hualin Yan | M | 66 |
Nanjing Audit University
| 16 jaar |
Yu Min Cai | F | 41 |
China Europe International Business School
| 2 jaar |
Wei Li | M | 45 |
China Europe International Business School
| 2 jaar |
Yun Qing Wang | M | 40 |
China Europe International Business School
| 2 jaar |
Wei Sun | M | 44 |
China Europe International Business School
| 2 jaar |
Yui Yu | M | 41 |
China Europe International Business School
| 2 jaar |
Jiong Wang | F | 55 |
China Europe International Business School
| 2 jaar |
Cheng Hu Shi | M | 49 |
China Europe International Business School
| 2 jaar |
Yi Wang | M | 44 |
Nanjing Audit University
| - |
Yan Yan Zhang | F | 42 |
China Europe International Business School
| 2 jaar |
Yi Gang Xu | M | 50 |
China Europe International Business School
| 2 jaar |
Qingda Heng | M | 49 |
China Europe International Business School
| 2 jaar |
Jing Lv | M | 50 |
China Europe International Business School
| 2 jaar |
Xu Zhang | M | 53 |
China Europe International Business School
| 2 jaar |
Hai Cheng Huang | M | 39 |
China Europe International Business School
| 2 jaar |
Yuan Yuan Wei | F | - |
China Europe International Business School
| 4 jaar |
Hui Duan | M | 45 |
China Europe International Business School
| 2 jaar |
Zhen Hui Wang | M | 49 |
China Europe International Business School
| 2 jaar |
Qiang Gao | M | 55 |
China Europe International Business School
| 2 jaar |
Xiao Huan Chen | M | 42 |
China Europe International Business School
| 2 jaar |
Zi Quan Wang | M | 57 |
China Europe International Business School
| 2 jaar |
Xin Hao He | M | 43 |
China Europe International Business School
| 2 jaar |
Zhen Yang | M | 44 |
China Europe International Business School
| 2 jaar |
Shi Qi Liu | M | 58 |
China Europe International Business School
| 2 jaar |
Yi Huang | M | 39 |
China Europe International Business School
| 2 jaar |
Li Ang Li | M | 45 |
China Europe International Business School
| 2 jaar |
Jun Xu | M | 50 |
China Europe International Business School
| 2 jaar |
Shou Wu Xie | M | 41 |
Nanjing Audit University
| 4 jaar |
Ke Li | F | 50 |
China Europe International Business School
| 2 jaar |
Jiting Peng | M | - |
China Europe International Business School
| 2 jaar |
Yuan Xue | F | 41 |
Nanjing Audit University
| 4 jaar |
Chen Wei | M | 38 |
China Europe International Business School
| 2 jaar |
Qi Cheng | M | 44 |
China Europe International Business School
| 2 jaar |
Yun Gao | F | 35 |
China Europe International Business School
| 2 jaar |
Guang Xian Zhu | M | 46 |
China Europe International Business School
| 2 jaar |
Xiao Jiang Han | M | 42 |
Nanjing Audit University
| 4 jaar |
Changzheng Chen | M | 44 |
China Europe International Business School
| 2 jaar |
Li Liu | F | 40 |
China Europe International Business School
| 2 jaar |
Peng Cui | M | 47 |
China Europe International Business School
| 2 jaar |
Hui Kong | M | 37 |
China Europe International Business School
| 2 jaar |
Feng Yu | M | 47 |
China Europe International Business School
| 2 jaar |
Yang Li | M | 49 |
China Europe International Business School
| 2 jaar |
Hung Man Wang | M | 36 |
China Europe International Business School
| 2 jaar |
Zhao Heng Lu | M | 60 |
China Europe International Business School
| 2 jaar |
Yuan Yu Lin | M | 47 |
China Europe International Business School
| 2 jaar |
Jun Xian Wu | M | 41 |
Nanjing Audit University
| 4 jaar |
Tong Li | F | 49 |
China Europe International Business School
| 2 jaar |
Bo Wang | M | 48 |
China Europe International Business School
| 2 jaar |
Li Cheng | M | 42 |
China Europe International Business School
| 2 jaar |
Kuan Yun Xia | M | 62 |
China Europe International Business School
| 2 jaar |
Ying Cai | M | 49 |
China Europe International Business School
| 2 jaar |
Min Wu | M | 55 |
China Europe International Business School
| 2 jaar |
Jia Xing Xing | M | 52 |
China Europe International Business School
| 2 jaar |
Tao Yuan Pan | M | 56 |
China Europe International Business School
| 2 jaar |
Yu Ping Xie | F | 50 |
China Europe International Business School
| 2 jaar |
Xiao Ou Xu | F | 51 |
China Europe International Business School
| 2 jaar |
Yue Xu | M | 49 |
China Europe International Business School
| 2 jaar |
Hua Xia | M | 57 |
China Europe International Business School
| 2 jaar |
Shun Wen Zhang | M | 58 |
China Europe International Business School
| 2 jaar |
Qiang Shi | M | 41 |
China Europe International Business School
| 1 jaar |
Cheng Lien Chen | M | 45 |
China Europe International Business School
| 2 jaar |
Dong Zhi Wang | M | 56 |
China Europe International Business School
| 2 jaar |
Lu Yi Li | F | 44 |
China Europe International Business School
| 2 jaar |
Wei Li Hong | M | 61 |
China Europe International Business School
| 2 jaar |
Fei Chen | F | 43 |
China Europe International Business School
| 1 jaar |
Qing Song Jiang | M | 52 |
China Europe International Business School
| 2 jaar |
Hui Peng Zhang | M | 42 |
China Europe International Business School
| 2 jaar |
Jia Yan | F | 43 |
Nanjing Audit University
| 4 jaar |
Sheng Jun Zhao | M | 42 |
China Europe International Business School
| 2 jaar |
Shu Jian Li | M | 54 |
China Europe International Business School
| 1 jaar |
Chun Hua Liu | M | 42 |
Nanjing Audit University
| 4 jaar |
Yi Song | F | 41 |
China Europe International Business School
| 2 jaar |
Yi Jing Feng | M | 42 |
Nanjing Audit University
| 4 jaar |
Xin Guan | F | 42 |
China Europe International Business School
| 2 jaar |
Yu Ping He | M | 51 |
China Europe International Business School
| 2 jaar |
Peng Zhuo Zeng | M | 35 |
Nanjing Audit University
| 4 jaar |
Hua Yang | M | 43 |
Nanjing Audit University
| 4 jaar |
Qin Ye Xu | F | 41 |
Nanjing Audit University
| 4 jaar |
Jun Kan Zhu | M | 41 |
Nanjing Audit University
| 4 jaar |
Xin Ji Chen | M | 38 |
China Europe International Business School
| 1 jaar |
Wei Rong Yao | M | 53 |
Nanjing Audit University
| 4 jaar |
Hai Qiu Guo | M | 49 |
China Europe International Business School
| 2 jaar |
Yi Qing Chen | M | 40 |
China Europe International Business School
| 2 jaar |
Bin Xi | M | 48 |
China Europe International Business School
| 2 jaar |
Ya Yun Li | F | - |
China Europe International Business School
| 1 jaar |
Lun Wong | M | 36 |
China Europe International Business School
| 2 jaar |
Hai Quan Wu | M | 45 |
China Europe International Business School
| 2 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
China | 100 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties